ResMed Launches AirFit F30i CPAP Mask, Widens Client Base

研究推出AirFit F30i CPAP面罩,宽客户端

2020/01/21 00:00  Zacks Equity Research

ResMed Inc. (RMD-Free Report) launched AirFit F30i, which is its first tube-up, full-face continuous positive airway pressure (CPAP) mask. With the launch, the company has completed its full-face mask portfolio in the market.

With the launch, the full-face CPAP users will now have an option of choosing among the type of connection (tube-up or tube-down), cushion styles (compact under-the-nose or traditional over-the-nose) as well as memory foam versus silicone cushion. AirFit F30i, which is being preferred by customers for features like a dependable seal and a comfortable under-the-nose fit for active sleepers, also completes ResMed’s Freedom category of tube-up masks.

Notably, other offerings like nasal tube-up AirFit N30i (released in January 2019) and nasal pillows tube-up AirFit P30i (released in April 2019) are available for users. With the latest launch, ResMed aims to strengthen its Sleep and Respiratory Care segment globally.

20200121211128668d2469bca2o01ysk

Significance of the Launch

The company believes that the design of AirFit F30i will make it easier for users to sleep in any position, without any soreness or irritation on the nasal bridge. Also, users need not take off the mask, while adjusting the tubing.

The company has presented favorable outcomes in a direct comparison study, where most patients preferred AirFit F30i over other full-face masks available in the market based on its design.

Industry Prospects

Per a report by , the global respiratory care devices market is expected to reach $31.8 billion by 2024 from $20.6 billion in 2019, witnessing a CAGR of 9.1%. Factors like rising demand for enhanced portable and compact respiratory care devices, growing demand for multimodal ventilation, and the increasing adoption of non-invasive ventilation are likely to drive the market.

Given the market potential, the launch has been timed well.

Recent Developments

ResMed launched AirFit N30, the first tube-down nasal cradle CPAP mask with a front-facing tube, in October 2019. With the launch, the company broadened its treatment option for sleep apnea.

Further, in October, ResMed entered a partnership with Cerner Corporation (-) to help care providers make better treatment decisions, manage costs, and deliver seamless care in both health systems and home.

Price Performance

Shares of ResMed have gained 36.7% in the past year compared with the ’s 16.2% growth.

Zacks Rank & Key Picks

Currently, the company carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the broader medical space are Haemonetics Corporation (-) and Medtronic plc (-) .

Haemonetics currently sports a Zacks Rank #1 (Strong Buy) and has a projected long-term earnings growth rate of 13.5%. You can see

Medtronic’s long-term earnings growth rate is expected at 7.4%. It currently has a Zacks Rank #2 (Buy).

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

ResMed公司(RMD-Free Report)推出AirFit F30i,这是它的第一个管上,全脸持续气道正压(CPAP)面具。随着推出,该公司已经完成了其在市场上的全面罩组合.

随着推出,全脸cpp用户现在将有一个选择的连接类型(管上或管下),缓冲风格(紧凑的鼻子下或传统的鼻过鼻)以及记忆泡沫与硅垫。AirFitF30i,这是客户首选的功能,如可靠的密封和舒适的鼻子下适合主动睡眠者,也完成了ResMed的自由类别的管-上面具。

值得注意的是,其他产品,如鼻管上升AirFit N30i(发布于2019年1月)和鼻枕头管管AirFit P30i(发布于2019年4月)是提供给用户。随着最新的推出,ResMed的目标是加强其在全球的睡眠和呼吸护理部门。

20200121211128668d2469bca2o01ysk

发射的意义

该公司相信,AirFitF30i的设计将使用户更容易在任何位置睡觉,而不会在鼻梁上感到疼痛或烦躁。此外,用户不需要脱下口罩,同时调整油管。

该公司在一项直接比较研究中展示了良好的效果,大多数患者更喜欢AirFitF30i,而不是根据其设计在市场上提供的其他全面罩。

产业前景

根据一份报告,到2024年,全球呼吸保健设备市场预计将从2019年的206亿美元增至318亿美元,CAGR为9.1%。增加便携式和紧凑的呼吸护理设备的需求,多式通风的需求不断增长,以及非侵入性通气的使用越来越多,这些因素都很可能会推动市场的发展。

鉴于市场潜力,此次上市时机已经很好。

最近的发展

ResMed推出了AirFit N30,第一个管下鼻摇篮CPAP面罩与一个正面的管,在2019年10月。随着这项计划的推出,该公司扩大了对睡眠呼吸暂停的治疗方案。

此外,在10月,ResMed与Cerner公司(-)建立了合作伙伴关系,以帮助护理提供者做出更好的治疗决定,管理成本,并在保健系统和家庭中提供无缝护理。

价格绩效

在过去一年里,ResMed的股价上涨了36.7%,而去年的涨幅为16.2%。

ZackRank&Key Pick

目前,该公司有一个ZackRank#3(持有)。

一些排名较好的股票从更广阔的医疗领域是血液科学公司(-)和Medtronic plc(-)。

Hemonetics目前拥有一个ZackRank#1(强力购买),预计长期收益增长率为13.5%。你可以看到

美敦力的长期盈利增长率预计为7.4%.它目前有一个ZackRank#2(购买)。

更多股票新闻:这比iPhone大!

它可能成为所有技术革命的之母。苹果在10年内仅售出10亿部iPhone,但一项新的突破有望在短短3年内创造出270亿台以上的设备,创造出一个价值1.7万亿美元的市场。

扎克斯刚刚发布了一份特别报告,突出了这一迅速出现的现象和利用这一现象的6个因素。如果你现在不买,你可能会在2020年踢自己的脚。

免责声明:中文翻译由腾讯翻译君提供支持,富途对翻译信息的准确性或可靠性所造成的任何损失不承担任何责任。

Copyright©2019 FUTU. All rights reserved. FUTU does not provide any investment advice.